DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $503,551,948 | +53.3% | 2,029,633 | +48.3% | 0.10% | +56.7% |
| Q2 2023 | $328,567,200 | -36.0% | 1,369,030 | -32.8% | 0.07% | -39.1% |
| Q1 2023 | $513,427,659 | +11.9% | 2,037,088 | +17.9% | 0.11% | -5.2% |
| Q4 2022 | $458,670,445 | +39.3% | 1,728,093 | +35.6% | 0.12% | +36.5% |
| Q3 2022 | $329,213,000 | +10.0% | 1,274,591 | +8.0% | 0.08% | +14.9% |
| Q2 2022 | $299,165,000 | -18.7% | 1,180,041 | -5.9% | 0.07% | +17.5% |
| Q1 2022 | $367,834,000 | -65.5% | 1,253,991 | -61.3% | 0.06% | +96.9% |
| Q4 2021 | $1,065,430,000 | +64.3% | 3,238,294 | +52.0% | 0.03% | -63.2% |
| Q3 2021 | $648,394,000 | +41.8% | 2,129,791 | +25.0% | 0.09% | +33.8% |
| Q2 2021 | $457,371,000 | +120.8% | 1,704,317 | +85.2% | 0.06% | +97.0% |
| Q1 2021 | $207,123,000 | -65.4% | 920,228 | -65.8% | 0.03% | -32.7% |
| Q4 2020 | $598,400,000 | +155.3% | 2,693,792 | +147.5% | 0.05% | +11.4% |
| Q3 2020 | $234,347,000 | -8.4% | 1,088,321 | -24.8% | 0.04% | -27.9% |
| Q2 2020 | $255,967,000 | -8.0% | 1,447,530 | -28.0% | 0.06% | -31.5% |
| Q1 2020 | $278,106,000 | +25.3% | 2,009,292 | +39.0% | 0.09% | +41.3% |
| Q4 2019 | $221,929,000 | +222.2% | 1,445,977 | +203.2% | 0.06% | +173.9% |
| Q3 2019 | $68,878,000 | -55.5% | 476,895 | -56.0% | 0.02% | +21.1% |
| Q2 2019 | $154,829,000 | +193.5% | 1,083,341 | +171.1% | 0.02% | -13.6% |
| Q1 2019 | $52,755,000 | +50.3% | 399,600 | +17.4% | 0.02% | +57.1% |
| Q4 2018 | $35,102,000 | -27.5% | 340,400 | -23.6% | 0.01% | -12.5% |
| Q3 2018 | $48,387,000 | -14.1% | 445,300 | -22.0% | 0.02% | -15.8% |
| Q2 2018 | $56,333,000 | +21.4% | 570,866 | +20.5% | 0.02% | +11.8% |
| Q1 2018 | $46,384,000 | -12.7% | 473,743 | -17.3% | 0.02% | -10.5% |
| Q4 2017 | $53,162,000 | -5.4% | 572,741 | -12.6% | 0.02% | -9.5% |
| Q3 2017 | $56,205,000 | +32.1% | 655,225 | +30.0% | 0.02% | +10.5% |
| Q2 2017 | $42,540,000 | -10.3% | 504,085 | -9.1% | 0.02% | -20.8% |
| Q1 2017 | $47,427,000 | -36.6% | 554,500 | -42.3% | 0.02% | -36.8% |
| Q4 2016 | $74,843,000 | -4.3% | 961,500 | -3.7% | 0.04% | 0.0% |
| Q3 2016 | $78,235,000 | -8.7% | 998,021 | +17.6% | 0.04% | -15.6% |
| Q2 2016 | $85,701,000 | +41.2% | 848,521 | +32.6% | 0.04% | +40.6% |
| Q1 2016 | $60,693,000 | -70.9% | 639,821 | -71.5% | 0.03% | -66.7% |
| Q4 2015 | $208,715,000 | +71.2% | 2,247,149 | +57.1% | 0.10% | +84.6% |
| Q3 2015 | $121,910,000 | -41.7% | 1,430,712 | -41.5% | 0.05% | -41.6% |
| Q2 2015 | $209,213,000 | +69.4% | 2,444,367 | +68.0% | 0.09% | +58.9% |
| Q1 2015 | $123,495,000 | +20.7% | 1,454,604 | +21.9% | 0.06% | +36.6% |
| Q4 2014 | $102,297,000 | +20.3% | 1,193,526 | +6.7% | 0.04% | +28.1% |
| Q3 2014 | $85,002,000 | +9.5% | 1,118,742 | +13.5% | 0.03% | -3.0% |
| Q2 2014 | $77,629,000 | +84.5% | 986,001 | +75.8% | 0.03% | +65.0% |
| Q1 2014 | $42,066,000 | -26.5% | 560,888 | -24.4% | 0.02% | -23.1% |
| Q4 2013 | $57,252,000 | +106.0% | 741,599 | +84.9% | 0.03% | +73.3% |
| Q3 2013 | $27,796,000 | -52.6% | 400,979 | -56.7% | 0.02% | -54.5% |
| Q2 2013 | $58,648,000 | – | 926,500 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |